NCT05599828View on ClinicalTrials.gov

A Study to Evaluate the Impact of Acid-reducing Agents on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

July 17, 2020

Primary Completion Date

September 13, 2020

Study Completion Date

September 13, 2020

Conditions
Healthy Participants
Interventions
DRUG

AMG 510

Oral Tablet

DRUG

Omeprazole

Capsule

DRUG

Famotidine

Tablet

Trial Locations (1)

75247

Covance Clinical Research Unit, Inc, Dallas

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY